Legacy Private Trust Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Legacy Private Trust reduced its stake in Celgene Corporation by 16.48% during the most recent quarter end. The investment management company now holds a total of 33,176 shares of Celgene Corporation which is valued at $3,372,009 after selling 6,545 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Celgene Corporation makes up approximately 0.47% of Legacy Private Trust’s portfolio.

Other Hedge Funds, Including , Canandaigua National Bank Trust Co reduced its stake in CELG by selling 192 shares or 1.64% in the most recent quarter. The Hedge Fund company now holds 11,543 shares of CELG which is valued at $1,173,231. Celgene Corporation makes up approx 0.35% of Canandaigua National Bank Trust Co’s portfolio.Gradient Investments boosted its stake in CELG in the latest quarter, The investment management firm added 29 additional shares and now holds a total of 3,123 shares of Celgene Corporation which is valued at $325,635. Celgene Corporation makes up approx 0.03% of Gradient Investments’s portfolio.Cupps Capital Management reduced its stake in CELG by selling 12,759 shares or 99.13% in the most recent quarter. The Hedge Fund company now holds 112 shares of CELG which is valued at $11,678. Celgene Corporation makes up approx 0.01% of Cupps Capital Management’s portfolio. Simplex Trading sold out all of its stake in CELG during the most recent quarter. The investment firm sold 116,614 shares of CELG which is valued $12,136,019.Washington Trust Bank reduced its stake in CELG by selling 2,185 shares or 37.65% in the most recent quarter. The Hedge Fund company now holds 3,619 shares of CELG which is valued at $381,045. Celgene Corporation makes up approx 0.09% of Washington Trust Bank’s portfolio.

Celgene Corporation closed down -2.63 points or -2.52% at $101.64 with 34,28,438 shares getting traded on Tuesday. Post opening the session at $103.6, the shares hit an intraday low of $101.021 and an intraday high of $103.881 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.